Kindlin-2 controls sensitivity of prostate cancer cells to cisplatin-induced cell death

Cancer Letters

Volumn 299, Issue 1, 2010, Pages 54-62

  Gong, Xiaowei ^a,c   An, Zhengwen ^a   Wang, Yunling ^a   Guan, Lizhao ^b   Fang, Weigang ^b   Strömblad, Staffan ^a   Jiang, Yong ^c   Zhang, Hongquan ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Cell death; Cisplatin; Kindlin 2; Prostate cancer

Indexed keywords

ANDROGEN; CISPLATIN; KINDLIN 2; PROTEIN BCL XL; REGULATOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MEMBRANE PROTEIN; MIG2B PROTEIN, HUMAN; PROTEIN BCL 2; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL PROTECTION; CELL STRAIN LNCAP; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; CHEMISTRY; DRUG EFFECTS; PATHOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; HUMANS; MALE; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE;

EID: 77957913447     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.08.003     Document Type: Article

References (36)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008, CA. Cancer J. Clin. 2008, 58:71-96.
2. Dhar S., Gu F.X., Langer R., Farokhzad O.C., Lippard S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. USA 2008, 105:17356-17361.
3. Orlandi L., Binda M., Folini M., Bearzatto A., Villa R., Daidone M.G., Zaffaroni N. Ribozyme-mediated inhibition of PKCalpha sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis. Prostate 2003, 54:133-143.
4. Huan S.D., Stewart D.J., Aitken S.E., Segal R., Yau J.C. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. Am. J. Clin. Oncol. 1999, 22:471-474.
5. Culine S., El Demery M., Lamy P.J., Iborra F., Avances C., Pinguet F. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J. Urol. 2007, 178:844-848. (discussion 848).
6. Lu Y., Zhang X., Beheshti B., Zhang J. Adenoviral-mediated pHyde gene transfer and cisplatin additively inhibit human prostate cancer growth by enhancing apoptosis. Prostate 2009, 69:234-248.
7. Howard D.N., Chambers C., Cusano F. Efficacy vs. effectiveness - docetaxel and prednisone in hormone refractory prostate cancer. J. Oncol. Pharm. Pract. 2008, 14:45-49.
8. Machiels J.P., Mazzeo F., Clausse M., Filleul B., Marcelis L., Honhon B., D'Hondt L., Dopchie C., Verschaeve V., Duck L., Verhoeven D., Jousten P., Bonny M.A., Moxhon A.M., Tombal B., Kerger J. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 2008, 26:5261-5268.
9. Barabas K., Milner R., Lurie D., Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet. Comp. Oncol. 2008, 6:1-18.
10. Moriyama-Gonda N., Shiina H., Terashima M., Satoh K., Igawa M. Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptor-alpha. BJU. Int. 2008, 101:485-491.
11. Villar J., Quadri H.S., Song I., Tomita Y., Tirado O.M., Notario V. PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization. Cancer Res. 2009, 69:102-110.
12. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
13. Garcia-Alvarez B., de Pereda J.M., Calderwood D.A., Ulmer T.S., Critchley D., Campbell I.D., Ginsberg M.H., Liddington R.C. Structural determinants of integrin recognition by talin. Mol. Cell. 2003, 11:49-58.
14. Kim M., Carman C.V., Springer T.A. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science 2003, 301:1720-1725.
15. Lock J.G., Wehrle-Haller B., Stromblad S. Cell-matrix adhesion complexes: master control machinery of cell migration. Semin. Cancer Biol. 2008, 18:65-76.
16. Larjava H., Plow E.F., Wu C. Kindlins: essential regulators of integrin signalling and cell-matrix adhesion. EMBO. Rep. 2008, 9:1203-1208.
17. Montanez E., Ussar S., Schifferer M., Bosl M., Zent R., Moser M., Fassler R. Kindlin-2 controls bidirectional signaling of integrins. Genes Dev. 2008, 22:1325-1330.
18. Harburger D.S., Bouaouina M., Calderwood D.A. Kindlin-1 and -2 directly bind the C-terminal region of beta integrin cytoplasmic tails and exert integrin-specific activation effects. J. Biol. Chem. 2009, 284:11485-11497.
19. Ma Y.Q., Qin J., Wu C., Plow E.F. Kindlin-2 (Mig-2): a co-activator of beta3 integrins. J. Cell Biol. 2008, 181:439-446.
20. Shi X., Ma Y.Q., Tu Y., Chen K., Wu S., Fukuda K., Qin J., Plow E.F., Wu C. The MIG-2/integrin interaction strengthens cell-matrix adhesion and modulates cell motility. J. Biol. Chem. 2007, 282:20455-20466.
21. Dowling J.J., Gibbs E., Russell M., Goldman D., Minarcik J., Golden J.A., Feldman E.L. Kindlin-2 is an essential component of intercalated discs and is required for vertebrate cardiac structure and function. Circ. Res. 2008, 102:423-431.
22. Rogalski T.M., Mullen G.P., Gilbert M.M., Williams B.D., Moerman D.G. The UNC-112 gene in Caenorhabditis elegans encodes a novel component of cell-matrix adhesion structures required for integrin localization in the muscle cell membrane. J. Cell Biol. 2000, 150:253-264.
23. Tu Y., Wu S., Shi X., Chen K., Wu C. Migfilin and Mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation. Cell 2003, 113:37-47.
24. Ussar S., Wang H.V., Linder S., Fassler R., Moser M. The kindlins: subcellular localization and expression during murine development. Exp. Cell Res. 2006, 312:3142-3151.
25. Tadokoro S., Shattil S.J., Eto K., Tai V., Liddington R.C., de Pereda J.M., Ginsberg M.H., Calderwood D.A. Talin binding to integrin beta tails: a final common step in integrin activation. Science 2003, 302:103-106.
26. Kato K., Shiozawa T., Mitsushita J., Toda A., Horiuchi A., Nikaido T., Fujii S., Konishi I. Expression of the mitogen-inducible gene-2 (mig-2) is elevated in human uterine leiomyomas but not in leiomyosarcomas. Hum. Pathol. 2004, 35:55-60.
27. Z. An, K. Dobra, J.G. Lock, S. Stromblad, A. Hjerpe, H. Zhang, Kindlin-2 is expressed in malignant mesothelioma and is required for tumor cell adhesion and migration, Int. J. Cancer 2010 Febuary 2 (Epub ahead of print).
28. Lai-Cheong J.E., Ussar S., Arita K., Hart I.R., McGrath J.A. Colocalization of kindlin-1, kindlin-2, and migfilin at keratinocyte focal adhesion and relevance to the pathophysiology of Kindler syndrome. J. Invest. Dermatol. 2008, 128:2156-2165.
29. Kruger M., Moser M., Ussar S., Thievessen I., Luber C.A., Forner F., Schmidt S., Zanivan S., Fassler R., Mann M. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 2008, 134:353-364.
30. Herz C., Aumailley M., Schulte C., Schlotzer-Schrehardt U., Bruckner-Tuderman L., Has C. Kindlin-1 is a phosphoprotein involved in regulation of polarity, proliferation, and motility of epidermal keratinocytes. J. Biol. Chem. 2006, 281:36082-36090.
31. Weinstein E.J., Bourner M., Head R., Zakeri H., Bauer C., Mazzarella R. URP1: a member of a novel family of PH and FERM domain-containing membrane-associated proteins is significantly over-expressed in lung and colon carcinomas. Biochim. Biophys. Acta 2003, 1637:207-216.
32. Shi X., Wu C. A suppressive role of mitogen inducible gene-2 in mesenchymal cancer cell invasion. Mol. Cancer Res. 2008, 6:715-724.
33. Salido M., Larran J., Lopez A., Vilches J., Aparicio J. Etoposide sensitivity of human prostatic cancer cell lines PC-3, DU 145 and LNCaP. Histol. Histopathol. 1999, 14:125-134.
34. Ren A., Yan G., You B., Sun J. Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Res. 2008, 68:2266-2274.
35. Armstrong A.J., Creel P., Turnbull J., Moore C., Jaffe T.A., Haley S., Petros W., Yenser S., Gockerman J.P., Sleep D., Hurwitz H., George D.J. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin. Cancer Res. 2008, 14:6270-6276.
36. Heath E.I., Gaskins M., Pitot H.C., Pili R., Tan W., Marschke R., Liu G., Hillman D., Sarkar F., Sheng S., Erlichman C., Ivy P. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Prostate Cancer 2005, 4:138-141.